N4 Pharma Plc (LON:N4P – Get Free Report) shares rose 5.9% during trading on Wednesday . The company traded as high as GBX 0.45 ($0.01) and last traded at GBX 0.45 ($0.01). Approximately 506,331 shares changed hands during trading, a decline of 77% from the average daily volume of 2,216,324 shares. The stock had previously closed at GBX 0.43 ($0.01).
N4 Pharma Price Performance
The company has a market cap of £1.94 million, a PE ratio of -1.30 and a beta of -0.37. The company has a 50-day moving average price of GBX 0.56 and a two-hundred day moving average price of GBX 0.60.
About N4 Pharma
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
Further Reading
- Five stocks we like better than N4 Pharma
- The Basics of Support and Resistance
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- The 3 Best Fintech Stocks to Buy Now
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is the Hang Seng index?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
